Two high-growth mid-cap stocks to add to your watch list

Double-digit earnings growth, healthy balance sheets and high future potential have me watching these companies closely.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investing in the pharmaceutical industry can be a bit of a hit or miss exercise for retailer investors. While companies in the sector can enjoy sky-high margins and years of protected revenue thanks to patents, their share prices can also fluctuate wildly based on poor clinical trial results or a rival gazumping them with a new competitor drug.

That’s why I’ve got my eye on £2bn market cap UDG Healthcare (LSE: UDG), a provider of marketing, sales and packaging services for pharmaceutical firms. The company is exposed to the upside of rising global use of pharmaceutical products, as well as the trend among pharma firms to outsource non-core operations such as training local sales teams or educating healthcare professionals on how best to use their drugs.

This is where UDG shines and as it proves its worth with existing clients and expands the array of services it offers and moves into new countries, it’s bringing in ever larger partners. This is paying off with sales for the half year to March rising 15% year-on-year (y/y) in constant currency terms to $578.9m, and pre-tax profits leaping a full 29% during the period to $52.9m.

This impressive performance has continued into Q3 with good trading and new acquisitions leading management to raise its earnings per share guidance to between 17% to 19% ahead of last year’s 31.8 US cents. The bad news is that taking the midpoint of this estimate would give UDG a valuation of around 28.9 times full year earnings.

While I see plenty of reasons to believe UDG will continue to grow organically and through acquisitions, improve its margins and maintain a healthy balance sheet, this valuation is simply too stretched compared to historic averages to make me comfortable. However, I will be keeping a close eye on the company and wait patiently for a more reasonable valuation before considering beginning a position.

Electric growth potential 

Another mid-cap for which I’m awaiting a share price dip is the aptly named electronics components distributor Electrocomponents (LSE: ECM). The company serves as a middle-man between manufacturers and end users in industries ranging from utilities, to miners, electronics and manufacturers of all stripes.

The company’s growth is down to plain old macroeconomic growth across the globe as well as increasing consolidation in the sector that favours large players such as itself. Last year underlying sales grew 4.8% y/y and 17.1% in reported currency terms to £1,511m, while operating margins rose 240 basis points to 8.8% and boosted operating profit to £133m.

In the quarter to June, this growth has picked up as each of its three main trading regions, North America, Europe and Asia, grew revenue by at least 10% y/y. The combination of continued economic growth in each of these regions, small bolt-on acquisitions and increased investment in sales staff training bodes well for this growth continuing for some time to come.

Furthermore, with a highly cash generative business that produced free cash flow of £117m last year and net debt less than one times EBITDA, there’s plenty of potential for both future acquisitions and increased shareholder returns. I like Electrocomponents a lot, but its valuation of 25 times forward earnings is just a bit too expensive for my taste.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ian Pierce has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£15,000 in cash? I’d pick growth stocks like these for life-changing passive income

Millions of us invest for passive income. Here, Dr James Fox explains his recipe for success by focusing on high-potential…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Here’s my plan for long-term passive income

On the lookout for passive income stocks to buy, Stephen Wright is turning to one of Warren Buffett’s most famous…

Read more »

artificial intelligence investing algorithms
Growth Shares

Are British stock market investors missing out on the tech revolution?

British stock market investors continue to pile into ‘old-economy’ stocks. Is this a mistake in today’s increasingly digital world?

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

My 2 best US growth stocks to buy in November

I’ve just bought two US growth companies on my best stocks to buy now list, and I think they’re still…

Read more »

Investing Articles

£2k in savings? Here’s how I’d invest that to target a passive income of £4,629 a year

Harvey Jones examines how investing a modest sum like £2,000 and leaving it to grow for years can generate an…

Read more »

Renewable energies concept collage
Investing Articles

Down 20%! A sinking dividend stock to buy for passive income?

This dividend stock is spending £50m buying back its own shares while they trade at a discount and also planning…

Read more »

Investing Articles

I’d buy 32,128 shares of this UK dividend stock for £200 a month in passive income

Insider buying and an 8.1% dividend yield suggest this FTSE 250 stock could be a good pick for passive income,…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

As stock markets surge, here’s what Warren Buffett’s doing

Warren Buffett has been selling his largest investments! Should investors follow in his footsteps, or is there something else going…

Read more »